Targets › CD45
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Jun 2027.
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. (UniProt, P08575)
Open in Phaseline: the race on CD45, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fred Hutchinson Cancer Center | 211At-BC8-B10 Anti-CD45 monoclonal antibody conjugated to astatine-211 for pretargeted radioimmunotherap | CD45 | Phase 1 | Acute Lymphoblastic Leukemia | Jun 2027 |
| University of Pennsylvania | CD45BE-HSPC CD45 base edited hematopoietic stem and progenitor cells | CD45 | Phase 1 | B-Cell Non-Hodgkin Lymphoma (NHL) | Jul 2051 |
Acute Lymphoblastic Leukemia (1) B-Cell Non-Hodgkin Lymphoma (NHL) (1)
mixed (2)
Fred Hutchinson Cancer Center (1) University of Pennsylvania (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.